Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $10,899,350.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the firm’s stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $65.56, for a total transaction of $10,899,350.00. Following the completion of the transaction, the chief executive officer directly owned 8,941,533 shares in the company, valued at $586,206,903.48. This trade represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Tempus AI Stock Performance

Shares of NASDAQ TEM traded down $3.69 during trading on Friday, reaching $59.82. 6,347,981 shares of the stock traded hands, compared to its average volume of 5,555,039. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The stock has a market capitalization of $10.64 billion, a P/E ratio of -50.27 and a beta of 5.22. Tempus AI, Inc. has a 52-week low of $36.22 and a 52-week high of $104.32. The company has a 50-day moving average of $68.76 and a 200-day moving average of $73.88.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company had revenue of $334.21 million during the quarter, compared to analyst estimates of $328.89 million. During the same quarter last year, the firm posted ($0.46) earnings per share. The firm’s revenue was up 84.7% on a year-over-year basis. Analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on TEM. BTIG Research lifted their price target on shares of Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. TD Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. JPMorgan Chase & Co. decreased their price target on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. HC Wainwright lowered their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Finally, Canaccord Genuity Group reduced their price objective on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, December 22nd. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $87.20.

Institutional Investors Weigh In On Tempus AI

Large investors have recently made changes to their positions in the company. Cranbrook Wealth Management LLC acquired a new stake in shares of Tempus AI in the third quarter valued at $25,000. Concord Wealth Partners grew its holdings in Tempus AI by 308.0% in the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after buying an additional 308 shares during the last quarter. JPL Wealth Management LLC acquired a new stake in shares of Tempus AI during the 3rd quarter worth approximately $26,000. GAMMA Investing LLC acquired a new stake in shares of Tempus AI during the 3rd quarter worth about $28,000. Finally, Allworth Financial LP grew its position in Tempus AI by 5,000.0% during the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.